Understanding COVID-19-associated coagulopathy: From PIC to SIC or DIC

Area of Science:

• Medical Research
• Pathophysiology
• Hematology

Background:

• Coagulopathy, marked by elevated D-dimer, is frequent in COVID-19 patients.
• This condition correlates with a worse prognosis and increased risk of thrombosis.
• Severe COVID-19 cases exhibit a higher incidence of deep vein thrombosis and pulmonary embolism.

Purpose of the Study:

• To investigate the nature of coagulopathy in COVID-19.
• To differentiate pulmonary intravascular coagulopathy from systemic coagulopathies.
• To understand the progression of coagulation disorders in severe COVID-19.

Main Methods:

• Review of clinical data and laboratory findings in COVID-19 patients.
• Analysis of coagulation markers, including D-dimer levels.
• Comparison of COVID-19-associated coagulopathy with sepsis-induced coagulopathy and disseminated intravascular coagulation.

Main Results:

• Pulmonary intravascular coagulopathy is identified as the characteristic coagulopathy in COVID-19.
• This disorder is a local coagulation issue primarily affecting the lungs.
• Progression to systemic coagulopathy (sepsis-induced or disseminated intravascular coagulation) signifies worsening dysfunction.

Conclusions:

• Pulmonary intravascular coagulopathy is a distinct local lung disorder in COVID-19.
• The transition to systemic coagulopathy indicates disease progression.
• Understanding these coagulation abnormalities is crucial for elucidating severe COVID-19 pathophysiology.